You may very well be right Doc. Maybe I’m using the wrong terminology. They were never denied. They simply pulled out due to uncertainty and mitigating expense since the FDA kept coming back for more info.
Whether it be a re-application, or a pick up where we left off....it will be positive for the investor base to hear a new pursuit of RMAT in the very near future.
News 
Market Data 
Discover 
